Skip to main content
. Author manuscript; available in PMC: 2022 Feb 26.
Published in final edited form as: N Engl J Med. 2021 Aug 11;385(9):803–814. doi: 10.1056/NEJMoa2034031

Figure 3. Predictions for Serum Concentrations after Intravenous Administration of CIS43LS.

Figure 3.

Panels A, B, and C show the predicted median serum concentrations of CIS43LS (solid black lines) and 90% prediction intervals (5th to 95th percentiles [dashed black lines]) according to CIS43LS dose group. Values were calculated on the basis of Monte Carlo simulations with the use of a population pharmacokinetic model. The dose groups reflect administration of CIS43LS at 5 mg per kilogram of body weight (Panel A), 20 mg per kilogram (Panel B), and 40 mg per kilogram (Panel C). Observed CIS43LS concentrations (normalized for each of the respective doses) are overlayed for comparison (circles). Panel D shows the predicted median CIS43LS concentration after a hypothetical intravenous dose of 10 mg per kilogram (dashed gray line) as compared with those of the other doses used in the trial (solid lines).